 Pyrroles
"Pyrroles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Azoles of one NITROGEN and two double bonds that have aromatic chemical properties.
| Descriptor ID |
D011758
|
| MeSH Number(s) |
D03.383.129.578
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrroles".
Below are MeSH descriptors whose meaning is more specific than "Pyrroles".
This graph shows the total number of publications written about "Pyrroles" by people in this website by year, and whether "Pyrroles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1996 | 2 | 0 | 2 | | 1997 | 2 | 0 | 2 | | 1998 | 1 | 0 | 1 | | 2000 | 2 | 0 | 2 | | 2001 | 3 | 1 | 4 | | 2002 | 1 | 0 | 1 | | 2003 | 6 | 0 | 6 | | 2004 | 3 | 1 | 4 | | 2005 | 6 | 6 | 12 | | 2006 | 4 | 2 | 6 | | 2007 | 6 | 2 | 8 | | 2008 | 10 | 3 | 13 | | 2009 | 7 | 3 | 10 | | 2010 | 3 | 4 | 7 | | 2011 | 5 | 5 | 10 | | 2012 | 6 | 4 | 10 | | 2013 | 4 | 3 | 7 | | 2014 | 5 | 4 | 9 | | 2015 | 2 | 3 | 5 | | 2016 | 6 | 2 | 8 | | 2017 | 2 | 0 | 2 | | 2018 | 4 | 0 | 4 | | 2019 | 3 | 3 | 6 | | 2020 | 1 | 2 | 3 | | 2021 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyrroles" by people in Profiles.
-
Naing A, Powderly JD, Nemunaitis JJ, Luke JJ, Mansfield AS, Messersmith WA, Sahebjam S, LoRusso PM, Garrido-Laguna I, Leopold L, Geschwindt R, Ding K, Smith M, Berlin JD. Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. J Immunother Cancer. 2022 03; 10(3).
-
Rubin DT, Modesto I, Vermeire S, Danese S, Ng SC, Kwok KK, Koram N, Jones TV. Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis. Aliment Pharmacol Ther. 2022 02; 55(3):302-310.
-
Tetangco EP, Hanauer SB. 5-ASAs Combined With a Biologic or Tofacitinib: Predetermined Cost-Effectiveness? Am J Gastroenterol. 2021 09 01; 116(9):1958-1959.
-
Armstrong AJ, Nixon AB, Carmack A, Yang Q, Eisen T, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, George DJ, Halabi S. Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2021 06 15; 27(12):3317-3328.
-
Fenster M, Alayo QA, Khatiwada A, Wang W, Dimopoulos C, Gutierrez A, Ciorba MA, Christophi GP, Hirten RP, Ha C, Beniwal-Patel P, Cohen BL, Syal G, Yarur A, Patel A, Colombel JF, Pekow J, Ungaro RC, Rubin DT, Deepak P. Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium. Clin Gastroenterol Hepatol. 2021 10; 19(10):2207-2209.e3.
-
Deepak P, Alayo QA, Khatiwada A, Lin B, Fenster M, Dimopoulos C, Bader G, Weisshof R, Jacobs M, Gutierrez A, Ciorba MA, Christophi GP, Patel A, Hirten RP, Colombel JF, Rubin DT, Ha C, Beniwal-Patel P, Ungaro RC, Syal G, Pekow J, Cohen BL, Yarur A. Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021 08; 19(8):1592-1601.e3.
-
Hamilton E, O'Malley DM, O'Cearbhaill R, Cristea M, Fleming GF, Tariq B, Fong A, French D, Rossi M, Brickman D, Moore K. Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study. Gynecol Oncol. 2020 09; 158(3):640-645.
-
Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Ji T, Lihou CF, Zhen H, Féliz L, Vogel A. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020 05; 21(5):671-684.
-
Piperno-Neumann S, Larkin J, Carvajal RD, Luke JJ, Schwartz GK, Hodi FS, Sablin MP, Shoushtari AN, Szpakowski S, Chowdhury NR, Brannon AR, Ramkumar T, de Koning L, Derti A, Emery C, Yerramilli-Rao P, Kapiteijn E. Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071. Mol Cancer Ther. 2020 04; 19(4):1031-1039.
-
Gomez-Arteaga A, Margolskee E, Wei MT, van Besien K, Inghirami G, Horwitz S. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leuk Lymphoma. 2019 07; 60(7):1626-1631.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|